



**IS INFRAINGUINAL BYPASS A DYING PROCEDURE?**

**WHAT DO CONTEMPORARY OUTCOMES TELL US?**

---

**William P. Robinson, III MD**

**Division of Vascular and Endovascular Surgery**

**University of Virginia School of Medicine**

**Charlottesville, VA**

# DISCLOSURE

## William Robinson, MD

- No relevant financial relationship reported

# “Does anybody do lower extremity bypass anymore?”

and D femoro-popliteal disease:  
Mid-term outcomes from a single  
tertiary referral center

Jeffrey Lorne Grenville<sup>1</sup>, Kong Teng Tan<sup>2</sup>, Hadas Moshonov<sup>2</sup> and  
Dheeraj Kumar Rajan<sup>2</sup>

J Cardiovasc Surg (Torino). 2013 Dec;54(6):679-84.  
**Endovascular first as "preliminary approach" for  
critical limb ischemia and diabetic foot.**

Setacicci C, Sirignano P, Galzerano G, Mazzitelli G,  
Benevento D, Cappelli A, Setacci F

**Limb Salvage in Patients With  
Peripheral Arterial Disease Managed  
by **Endovascular First Approach****


Kyin Kyin May, MBBS<sup>1,2</sup>, Peter Ashley Robless, FRCR<sup>1,2</sup>,  
Harvinder Raj Singh Sidhu, FRCS<sup>3</sup>, Ben Soo Yen,  
and Pei Ho, FRCS<sup>1,2</sup>

Long-term limb salvage and survival after  
endovascular and open revascularization for critical  
limb ischemia after adoption of **endovascular-first  
approach** by vascular surgeons

Hasan H. Dosluoglu, MD,<sup>a,b</sup> Purandath Lall, MBBS,<sup>a,b</sup> Linda M. Harris, MD,<sup>b</sup> and  
Maciej L. Dryjski, MD,<sup>b</sup> Buffalo, NY




# Paradigm Shift in PAD Therapy



The Increase in Endovascular Interventions has outpaced the Decline in Bypass Surgery by More Than **3:1** in Medicare Patients



# Trends in PAD Therapy 2011-2014




- Stabilization of Bypass Utilization (18% of revascularizations to 15%) in Medicare beneficiaries ?
- Continued rapid growth in PVI due to growth of atherectomy




# Trends in CLI Therapy in Entire U.S. Population

National Inpatient Sample: Estimated 3 million admissions for CLI in U.S., 2003-2011

**FIGURE 5** Trends of Revascularization Strategies Among CLI Patients



**Surgery**




**PVI**



# Shift in PAD Therapy to Outpatient Endovascular


**CENTRAL ILLUSTRATION** Trends in PVI Among Medicare Beneficiaries



Establishment of Medicare “ambulatory payment classifications”




# Trends in PVI and Physician Specialty





# Implications of Increasing PVI



“There has been a significant increase in utilization of endovascular revascularization with a corresponding decrease in surgical revascularization, accompanied by a decrease in in-hospital death and major amputation rates in the United States during 2003 - 2011”.



# Infrainguinal Bypass in the Endovascular Era

Bypass has declined 60%  
over 20 years

Exponential Growth of PVI



Bypass utilized in 15-18%  
revascularizations for PAD

- Vascular Surgeons as well as interventionalists driving this trend
- PAD treatment moving to the outpatient setting
- The decline in utilization of bypass appears to be stabilizing

• *Is this justified?*

• What are the contemporary results of bypass vs. endovascular therapy?

# Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia

Michael S. Conte, MD,<sup>a</sup> Patrick J. Geraghty, MD,<sup>b</sup> Andrew W. Bradbury, MD,<sup>c</sup> Nathanael D. Hevelone, MPH,<sup>d</sup> Stuart R. Lipsitz, ScD,<sup>e</sup> Gregory L. Moneta, MD,<sup>f</sup> Mark R. Nehler, MD,<sup>g</sup> Richard J. Powell, MD,<sup>h</sup> and Anton N. Sidawy, MD,<sup>i</sup> *San Francisco, Calif; St. Louis, Mo; Birmingham, United Kingdom; Boston, Mass; Portland, Ore; Aurora, Colo; Hanover, NH; and Washington, DC*

- **Objective Performance Goals (OPGs) derived from historical controls against which new devices are compared**
- **Derived from results of lower extremity bypass with GSV (N=838) performed in three major randomized trials (1990-2007)**
- **Novel patient-centered efficacy endpoints**
  - *Major Adverse Limb Events (MALE)*
  - *Major Adverse Cardiovascular Events (MACE)*
- **Define key high risk groups with different expected outcomes**
  - **“Anatomic High Risk”: Infrapopliteal Disease**



# SVS OPGs for Revascularization for CLI

- Expected 30-day outcomes for CLI patients

<i>Outcome</i>	<i>30 day events (%; 95% CI)</i>	<i>Maximum allowable events (trial N = 392)</i>	<i>Safety OPG</i>
MACE	6.2% (4.7-8.1)	20 (5.1%, 3.1-7.8%)	8%
• Death	2.7%		
• MI	3.1%		
• CVA	1.0%		
MALE	6.1% (4.6-7.9)	18 (4.6%, 2.7-7.2)	8%
Amputation	1.9% (1.1-3.1)	5 (1.3%, 0.4-3.0)	3%



# CONTEMPORARY OUTCOMES OF BYPASS AND ENDOVASCULAR THERAPY FOR CLI?

## Lower Extremity Bypass and Endovascular Intervention for Critical Limb Ischemia Fail to Meet Society for Vascular Surgery's Objective Performance Goals for Limb-Related Outcomes in a Contemporary National Cohort

William P. Robinson, MD<sup>a</sup>, J. Hunter Mehaffey, MD<sup>b</sup>, Robert B. Hawkins, MD<sup>b</sup>, Megan Tracci, MD<sup>a</sup>, Mohammad Eslami, MD<sup>c</sup>, and Gilbert R. Upchurch, Jr. MD<sup>a</sup>

- Objective: To determine if contemporary real world treatment of CLI meets SVS OPG benchmarks
- Utilized NSQIP Vascular-Targeted Modules for LEB and Infrainguinal Endovascular Intervention, 2011-2015
  - >100 clinical variables



# Results: NSQIP cohort 2011-2015

**17,986 total Lower Extremity Revascularizations**

**10,738 LEB (60%)**

**7,248 IEI (40%)**



Exclude procedures for  
claudication and  
emergency procedures

**11,043 Revascularizations Performed for CLI**

**6,909 LEB (63%)**

**4,134 IEI (37%)**



Apply SVS OPG criteria:  
Exclude ESRD (1,164)  
Exclude bypass with prosthetic/  
composite / spliced conduit (2,520)

**Study Population: 7,359 OPG-Eligible Revascularizations**

**3,833 LEB (52%)**

**3,526 IEI (48%)**



# Revascularizations in OPG-Eligible Patients

Revascularizations for CLI in NSQIP in OPG-Eligible Patients	n =7359
Lower Extremity Bypass	n=3,833
Femoropopliteal bypass w/ single segment saphenous vein	1,865 (49%)
Femoral-tibial/pedal bypass w/ single segment saphenous vein	1,411 (37%)
Popliteal-tibial/pedal bypass w/ single segment saphenous vein	557 (15%)
Infrainguinal Endovascular Intervention	n=3,526
Femoropopliteal angioplasty/stenting/atherectomy	2,573 (73%)
Tibial angioplasty/stenting/atherectomy	953 (27%)



# Outcomes in OPG-eligible CLI cohort

Endpoint (%)	SVS OPG Safety Threshold	OPG (n=838)	LEB (n=3,833)	p-value <sup>a</sup>	IEI (n=3,526)	p-value <sup>b</sup>
MACE	<8%	6.2 [4.7, 8.1]	4.2 [4.1-4.3]	0.013	3.1 [3.0-3.2]	<0.0001
MALE	<8%	6.1 [4.6, 7.9]	9.0 [8.7-9.2]	0.007	9.7 [9.4-10.0]	0.001
Amputation	<3%	1.9 [1.1, 3.1]	3.7 [3.6-3.8]	0.009	4.3 [4.2-4.5]	<0.0001

<sup>a</sup> LEB vs OPG

<sup>b</sup> IEI vs. OPG



# Outcomes in Infrapopliteal CLI Revascularizations

Endpoint	SVS OPG Safety Threshold	OPG (n=505)	LEB (n=1,968)	p-value <sup>a</sup>	IEI (n=953)	p-value <sup>b</sup>
MACE	<10%	7.3 [5.2-10.0]	4.4 [4.3-4.6]	0.009	2.1 [2.0-2.2]	<0.0001
MALE	<9%	6.1 [4.2-8.6]	9.5 [9.1-9.8]	0.019	11.1 [10.4-11.8]	0.002
Amputation	<4%	2.2 [1.1-3.9]	4.1 [4.0-4.3]	0.040	6.4 [6.0-6.8]	0.0004

† defined as LEB to tibia/pedal target or IEI to tibial vessel

<sup>a</sup> LEB vs OPG

<sup>b</sup> IEI vs. OPG

**Lower extremity bypass for critical limb ischemia decreases major adverse limb events with equivalent cardiac risk compared with endovascular intervention**

J. Hunter Mehaffey, MD, Robert B. Hawkins, MD, Anna Fashandi, MD, Kenneth J. Cherry, MD, John A. Kern, MD, Irving L. Kron, MD, Gilbert R. Upchurch Jr, MD, *and* William P. Robinson, MD, *Charlottesville, Va*

**Objective: Compare outcomes of Lower Extremity Bypass and Infrainguinal Endovascular Intervention for critical limb ischemia in a propensity-matched cohort**

– NSQIP Vascular Targeted Modules 2011-2014



# Revascularizations in Matched Cohort

<b>Lower Extremity Bypass</b>	1924 (50%)
<b>Supragenicular Revascularization</b>	1384 (71.9%)
Femoropopliteal bypass w/ single segment saphenous vein	730 (52.7%)
Femoropopliteal bypass w/prosthetic/spliced vein/composite	654 (47.3%)
<b>Infragenicular Revascularization</b>	540 ( 28.1%)
Femoral distal bypass w/ single segment saphenous vein	244 (45.2%)
Femoral distal bypass w/ prosthetic/spliced vein/composite	147 (27.2%)
Popliteal distal w/ single segment saphenous vein	116 (21.5%)
Popliteal distal bypass w/ prosthetic/spliced vein/composite	33 (6.1%)
<b>Infrainguinal Endovascular Intervention</b>	1924 (50%)
<b>Supragenicular Revascularization</b>	1352 (70.3%)
Femoropopliteal angioplasty/stenting/atherectomy	1352
<b>Infragenicular Revascularization</b>	572 ( 29.7%)
Tibial angioplasty/stenting	572



# Outcomes: Bypass vs. Endovascular Intervention

Parameter	Endovascular	Open	p-value
<b>MALE</b>	<b>235 (12.2%)</b>	<b>177 (9.2%)</b>	<b>0.003</b>
Untreated Loss of Patency	32 (1.7%)	52 (2.7%)	0.03
Re-intervention	105 (5.5%)	93 (4.8%)	0.38
Amputation	131 (6.8%)	80 (4.2%)	0.0003

Parameter	Endovascular	Open	p-value
<b>MACE</b>	<b>72 (3.7%)</b>	<b>95 (4.9%)</b>	<b>0.07</b>
Stroke or MI	40 (2.1%)	54 (2.8%)	0.14
Mortality	41 (2.1%)	55 (2.9%)	0.15




# Conclusions

- Revascularization for CLI not meeting SVS OPGs and the outcomes achieved between 1990 and 2007 with bypass
- Bypass associated with superior limb outcomes at 30 days compared to endovascular intervention
- Cardiovascular morbidity/mortality surpassed the cardiovascular safety thresholds established by SVS OPGs
  - 30-day MACE similar between bypass and endovascular intervention
  - CV morbidity associated with revascularization for CLI continues to improve




# Epidemiologic shifts leading to more distal pattern of disease

## Increasing diabetes






No. of participants 8478 2168 2479 2299 2191 2901 3118 2781

## Decreasing Smoking






# The Real Problem: *Restenosis*






**Growing impact of restenosis on the surgical treatment of peripheral arterial disease. Jones D et al; JAHA 2013**





# BASIL: Impact of Treatment Received on Amputation-Free Survival



***“BAP was associated with a significantly higher failure rate than BSX. Most BAP patients ultimately required surgery. BSX outcomes after failed BAP are significantly worse than for BSX performed as a first revascularization attempt. BSX with vein offers the best long term AFS and OS.***



# Medicare & Medicaid, Payers, Employers Are Talking About “Value”



CENTERS FOR MEDICARE & MEDICAID SERVICES

## Roadmap for Implementing Value Driven Healthcare in the Traditional Medicare Fee-for-Service Program





# The value of infrainguinal bypass

- It is effective and durable.
- Performed with lower cardiovascular morbidity and mortality than thought
- Adaptable and effective in anatomically complex PAD
  - endovascular therapy more dependent on favorable lesion and anatomic characteristics
  - Epidemiologic trends (↑ elderly/DM/ ESRD) → Difficult anatomy likely to increase
- Necessary to treat the restenosis epidemic
- Cost –effective in tight financial times
  
- *No clear justification for widespread abandonment of bypass in favor of endovascular intervention*



# Thoughts on the Role of Lower Extremity Bypass

- Maintain and improve our skills/ techniques in infrainguinal bypass
- Maintain and improve our judgement in lower extremity arterial occlusive disease
  - open and endovascular treatment as complementary rather than competitive techniques
- Transmit bypass skills/judgement to next generation of vascular surgeons and trainees across disciplines

# Thank you





# Surgeon, not institution, case volume is associated with limb outcomes after lower extremity bypass for critical limb ischemia in the Vascular Quality Initiative



Lily E. Johnston, MD, MPH,<sup>a</sup> Margaret C. Tracci, MD, JD,<sup>a</sup> John A. Kern, MD,<sup>a,b</sup> Kenneth J. Cherry, MD,<sup>a</sup> Irving...

Institutional volume: 1-137 LEB per year (median 27)

Surgeon Volume: 1-52 LEB per year (median 5.7)

Annual Surgeon Volume independently associated with improved primary bypass patency and reduced MALE

Institutional LEB volume was not associated with MACES or MALES. However, average annual surgeon volume was independently associated with reduced MALES and primary patency. Institutional and surgeon volume did not predict MACES.

**Conclusions:** In contradistinction to previous studies, there was no association in this study between institutional LEB volume and outcomes after LEB. However, greater average annual surgeon volume was associated with improved primary patency and decreased risk of MALEs. Open LEB remains a safe and effective procedure for limb salvage. Limb-related outcomes in critical limb ischemia and claudication will be optimized if surgeons maintain adequate volume of LEB. (J Vasc Surg 2017;66:1457-63.)

